Nanobody Research Center, Guangxi Medical University, Nanning, Guangxi, 530021, China.
School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, 530021, China.
Theranostics. 2019 Oct 15;9(25):7792-7806. doi: 10.7150/thno.35486. eCollection 2019.
Therapeutic antibodies are one most significant advances in immunotherapy, the development of antibodies against disease-associated MHC-peptide complexes led to the introduction of TCR-like antibodies. TCR-like antibodies combine the recognition of intracellular proteins with the therapeutic potency and versatility of monoclonal antibodies (mAb), offering an unparalleled opportunity to expand the repertoire of therapeutic antibodies available to treat diseases like cancer. This review details the current state of TCR-like antibodies and describes their production, mechanisms as well as their applications. In addition, it presents an insight on the challenges that they must overcome in order to become commercially and clinically validated.
治疗性抗体是免疫疗法的重大进展之一，针对疾病相关 MHC-肽复合物的抗体的开发导致了 TCR 样抗体的出现。TCR 样抗体将细胞内蛋白的识别与单克隆抗体（mAb）的治疗效力和多功能性结合在一起，为治疗癌症等疾病的治疗性抗体提供了无与伦比的扩展机会。本文详细介绍了 TCR 样抗体的现状，并描述了它们的生产、作用机制及其应用。此外，本文还介绍了它们在成为商业和临床验证之前必须克服的挑战。
